Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system. The company operates as a single business segment centered on the development, commercialization, and support of its proprietary blood volume analysis technology used by healthcare providers.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$8.08 – $8.44
Volume1,514
Market cap$49M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for DXR.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for DXR.
Recent news
Company coverage with links to the original publishers.
Daxor Corporation announced the launch of a new outpatient Blood Volume Analysis (BVA) program at a healthcare facility in eastern Kansas through its turnkey ezBVA Lab send-out model. The service provides 98% accurate blood volume measurements within 24 hours without requiring capital equipment, enabling clinicians to optimize decongestion strategies and reduce hospital readmissions.
Daxor Corporation will exhibit its FDA-cleared Blood Volume Analyzer (BVA) for the first time at the 14th Annual Dysautonomia International Conference (July 9-12, 2026) in Texas. The company emphasizes how BVA provides objective plasma and red blood cell data to improve dysautonomia therapy, representing a shift from subjective symptom tracking to precision, data-driven diagnostics.
Daxor Corporation announced a definitive agreement to sell 765,958 shares of common stock at $11.75 per share to fundamental investors, raising approximately $9 million in gross proceeds. The offering is expected to close on January 26, 2026, with net proceeds intended for general corporate purposes and working capital. Lake Street Capital Markets is serving as the exclusive placement agent.
Daxor Corporation will participate in the Maxim Growth Summit in New York City, presenting its innovative Blood Volume Analysis (BVA) technology to institutional investors and featuring one-on-one meetings with potential investors.
Daxor Corporation, a leader in blood volume measurement technology, will showcase its innovative Blood Volume Analysis (BVA) at the MedAxiom Cardiovascular Transforum Spring 2025 conference. WellStar Health System will present findings on how BVA-driven strategies significantly reduced kidney injury following LVAD implantation.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Jan 5, 2018
$0.03
Jan 12, 2018
recurring
Dec 20, 2016
$0.03
Dec 29, 2016
recurring
Dec 18, 2015
$0.04
Dec 29, 2015
recurring
Dec 4, 2014
$0.03
Dec 26, 2014
recurring
Dec 5, 2013
$0.05
Dec 27, 2013
recurring
Stock splits
Historical share-structure events and their execution dates.